Unipharm was founded in 1975 in Israel and since its early days was a dominant player in the pharmaceutical arena in Israel.
We create value in the full pharmaceutical value chain from developing to manufacturing and successfully marketing generic pharmaceuticals. We take pride in doing this in an innovative, responsible and cost-efficient way.
We offer product portfolio consisting of a broad range of high quality generics for all major therapeutic areas. It is part of our long-term strategy to expand the product portfolio of off-patent blockbusters while at the same time offering a broader range of niche products within more narrow disease areas.
Unipharm’s products are developed in the CTD dossier format and produced in a manufacturing facility certified in compliance with Good Manufacturing Practices (GMP), which is recognized by the European Union (EU).
Unipharm is involved in intellectual activities.
In the current pharmaceutical-IP environment where major pharmaceutical companies are protecting their product with multiple patents, Unipharm has the capabilities of accurately evaluating a product’s patent protection suit and to act accordingly: either stay off the market until the patents expire, to circumvent the still valid patents or to try to invalidate the patent and launch a generic version as soon as legally possible.